Multikinase inhibition-mediated proliferative vitreoretinopathy therapy by nanoparticles in rabbits
Molecular Vision · 29.03.2025 · 31 · 142-157
DOI: 10.63500/mv_v31_142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Vision, online erschienen am 29.03.2025. Verfasst von Elif Arslan und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 3.0).
Abstract (Originalsprache)
Purpose
To investigate the efficacy of nanoparticles in treating proliferative vitreoretinopathy (PVR) through clinical observation, histology, and immunohistochemistry, despite unsatisfactory surgical outcomes and failed therapies for the current PVR treatment Design Twelve rabbits were divided into control and nintedanib (NTB) groups. The rabbits underwent weekly ophthalmologic examinations over a period of four weeks.
Methods
At the end of the fourth week, the rabbits’ eyes were removed for histological and immunohistochemical evaluation. Three additional rabbits outside the PVR model were administered a 0.5% NTB-loaded liposomal formulation in one eye. The drug concentrations in the vitreous samples were determined using high-pressure liquid chromatography on days 1, 7, 14, and 35.
Results
The PVR stages were low in the NTB group, and there was no significant difference between the NTB and control groups (p = 0.108). However, it is worth noting that the group treated with NTB had significantly fewer epiretinal membrane formations during the histological evaluation. In addition, the corrected fluorescence intensity measurement of the subjects for collagen-1 in the NTB group was significantly lower than that in the control group (p = 0.004). Most importantly, no significant adverse effects were observed.
Conclusions
Our study has provided preclinical support for a liposomal formulation containing NTB that, with single-dose administration, has the potential to be effective in vivo in preventing the development of PVR and its correlated pathologies without causing any significant side effects.
Zitieren
APA
Arslan, E., Ozturk, F., Uner, B., Tureli, S., Muftuoglu, S. F., & Tas, C. (2025). Multikinase inhibition-mediated proliferative vitreoretinopathy therapy by nanoparticles in rabbits. Molecular Vision, 31, 142-157. https://doi.org/10.63500/mv_v31_142
Vancouver
Arslan E, Ozturk F, Uner B, Tureli S, Muftuoglu SF, Tas C. Multikinase inhibition-mediated proliferative vitreoretinopathy therapy by nanoparticles in rabbits. Molecular Vision. 2025;31:142-157. doi:10.63500/mv_v31_142
BibTeX
@article{Arslan2025,
author = {Arslan, Elif and Ozturk, Faruk and Uner, Burcu and Tureli, Serkan and Muftuoglu, Sevda Fatma and Tas, Cetin},
title = {Multikinase inhibition-mediated proliferative vitreoretinopathy therapy by nanoparticles in rabbits},
journal = {Molecular Vision},
year = {2025},
volume = {31},
pages = {142--157},
doi = {10.63500/mv_v31_142}
}
EUVIMED